1 citations
,
July 2019 in “British Journal of Dermatology” This study found that 15% minoxidil topical solution was more effective than low-level laser therapy in improving hair regrowth and patient satisfaction in individuals with androgenetic alopecia.
1 citations
,
January 2015 in “Journal of Aesthetic & Reconstructive Surgery” This review discusses techniques for harvesting follicular units, medical treatments for androgenetic alopecia, and potential future advancements in hair restoration therapy, but it reports no new clinical results.
1 citations
,
May 2014 in “Hair transplant forum international” This commentary explores the challenges and considerations in treating female pattern hair loss, with no new clinical findings reported.
August 2026 in “Journal of Pharmacology Genetics and Molecular Biology” This review evaluates androgenetic alopecia treatments, highlighting both current options like minoxidil, finasteride, and low-level light therapy, and emerging therapies such as platelet-rich plasma and complex combination treatments, noting their potential and challenges.
July 2026 in “Research Society and Development” This study reviewed recent advancements in treating androgenetic alopecia, reporting that while minoxidil and 5-alpha-reductase inhibitors remain well-supported treatments, emerging therapies like microneedling, platelet-rich plasma, low-level laser, and regenerative medicine show promising complementary results.
July 2026 in “IntechOpen eBooks” This review highlights the challenges and management strategies associated with persistent chemotherapy-induced alopecia, detailing the psychosocial impacts, follicular pathobiology, and available treatments such as scalp cooling and minoxidil, ultimately proposing a clinical algorithm to transform it into a preventable and manageable condition.
July 2026 in “International Journal of Drug Delivery Technology” This review of non-surgical treatments for androgenetic alopecia reports that combination therapies, particularly platelet-rich plasma with low-level laser therapy, tend to be more effective than using each treatment alone.
July 2026 in “Journal of the American Academy of Dermatology” Rosemary oil may be a promising and affordable treatment for hair loss.
June 2026 in “Skin Appendage Disorders” This review discusses diffuse unpatterned alopecia (DUPA) as an understudied variant of androgenetic alopecia, summarizing its presentation and management while calling for further research to better understand its distinct characteristics.
This study systematically reviewed androgenetic alopecia's clinical features, mechanisms, and treatments, highlighting that current drugs have limitations but emerging therapies and personalized treatment strategies could enhance efficacy and outcomes.
June 2026 in “Facial Plastic Surgery” This review concluded that non-surgical hair restoration methods, such as pharmacologic and regenerative therapies, are important for delaying or supplementing surgical treatments when used properly.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review discusses the pathophysiology, molecular events, and therapeutic options for androgenetic alopecia, but reports no new clinical findings.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review explores the complex pathophysiology of androgenetic alopecia, highlighting genetic factors, androgen metabolism, and emerging therapies such as platelet-rich plasma and low-level laser therapy, but notes that no ultimate cure exists and treatments focus on slowing progression and promoting hair growth.
This source discusses treatment options for androgenetic alopecia in post-operative transgender women, highlighting traditional therapies like minoxidil and finasteride and promising alternatives such as platelet-rich plasma and low-level laser therapy, noting that treatment decisions depend on individual patient circumstances and the availability of specialized research.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This source provides an overview of various treatment options for androgenetic alopecia in post-operative transgender women, highlighting both traditional methods like minoxidil and finasteride, and newer alternatives such as PRP and LLLT, with the choice depending on individual patient circumstances and research availability.
May 2026 in “Skin Appendage Disorders” This study determined that low-level light therapy and fractional lasers are effective and safe treatments for androgenetic alopecia, especially when combined with other agents like minoxidil, PRP, or growth factors.
This study found that low-level light therapy and fractional lasers are effective and safe treatments for androgenetic alopecia, with the greatest improvements in hair density and thickness seen in combination therapies.
This study reports that low-level light therapy and fractional lasers are effective and safe treatments for androgenetic alopecia, with more pronounced results when combined with other therapies.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review article examines recent advances in understanding and managing various types of alopecia, highlighting modern therapeutic strategies such as individualized treatment plans, combination therapies, and regenerative approaches aimed at improving hair regrowth and minimizing adverse effects.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review article reports on the latest therapeutic strategies for alopecia, highlighting advancements in personalized treatment plans, combination therapies, and regenerative approaches, with a focus on improving hair regrowth and minimizing side effects through modern treatments like stem cell therapy and Janus kinase inhibitors.
This review highlights that managing androgenetic alopecia in women involves a variety of treatments including approved drugs like minoxidil, as well as newer therapies such as PRP and LLLT, yet emphasizes the need for more research on long-term outcomes and treatment standardization.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review discusses various management strategies for androgenetic alopecia in women, including approved drugs like minoxidil and emerging therapies such as PRP and LLLT, highlighting the need for research on long-term outcomes and standardization.
This review concluded that laser-based therapies, particularly low-level lasers and fractional ablative lasers, are effective for treating hair loss, with combination therapies showing superior efficacy compared to monotherapies.
March 2026 in “Bulletin of the Medical Institute of Continuing Education” This review explores recent insights into the causes, clinical features, diagnosis, and comprehensive treatments of female-pattern hair loss, emphasizing the importance of trichoscopy and highlighting approaches like nutritional correction and various therapies including low-intensity lasers and PRP.
March 2026 in “Open MIND” This review evaluates PRP, microneedling, and LLLT for alopecia and telogen effluvium, reporting improvements of 30-40% but offers no new clinical data.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study confirmed that minoxidil is effective for female androgenic alopecia, with suggested additional benefits from therapies like LLLT and PRP, although more research is needed.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study confirms minoxidil's effectiveness for treating female androgenic alopecia and suggests possible added benefits from therapies like LLLT and PRP, though further research is needed.
February 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study reviewed treatments and findings related to male androgenetic alopecia, noting that topical minoxidil and oral finasteride are effective for slowing hair loss, while newer interventions like PRP and microneedling show promise.
February 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review discusses the epidemiology, pathophysiology, diagnosis, and management of male androgenetic alopecia, noting that combination treatments, including FDA-approved and emerging therapies, may improve outcomes without added side effects.
January 2026 in “Dermatology Review” This review discusses androgenetic alopecia, outlining its genetic and hormonal causes, and summarizes current and emerging treatments like minoxidil, finasteride, and low-dose oral therapies, emphasizing the need for more research to confirm the efficacy and safety of newer approaches.